Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0000950170-25-029185
Filing Date
2025-02-27
Accepted
2025-02-27 16:55:48
Documents
17
Effectiveness Date
2025-02-27

Document Format Files

Seq Description Document Type Size
1 S-8 janx-20250227.htm S-8 125348
2 EX-5.1 janx-ex5_1.htm EX-5.1 19858
3 EX-23.1 janx-ex23_1.htm EX-23.1 3020
4 EX-FILING FEES janx_exfilingfees.htm   iXBRL EX-FILING FEES 40292
5 GRAPHIC img151594875_0.jpg GRAPHIC 5995
6 GRAPHIC img151594875_1.jpg GRAPHIC 5995
  Complete submission text file 0000950170-25-029185.txt   359898

Data Files

Seq Description Document Type Size
19 EXTRACTED XBRL INSTANCE DOCUMENT janx_exfilingfees_htm.xml XML 15063
Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Filer) CIK: 0001817713 (see all company filings)

EIN.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-285357 | Film No.: 25680320
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)